

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: _____ :
Tomoki Kato

APPLICATION SERIAL NO.: 10/595,948 : Examiner: Unknown

INTERNATIONAL FILING DATE: November 10, 2004 : Group Art Unit: Unknown

TITLE: Quinolonecarboxylic Acid Compounds Having 5-:
HT4 Receptor Agonistic Activity

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

FILING OF MISSING PARTS OF APPLICATION
PURSUANT TO NOTICE ON FORM PTO-1533

This is in response to the communication mailed on March 27, 2008, the term for response having been extended by one (1) month to June 27, 2008 by including the appropriate fee and petition herewith. The communication was a Notification To Comply With Requirements For Patent Applications Containing Nucleotide And/or Amino Acid Sequence Disclosures (hereinafter "Notification to Comply").


The undersigned spoke with Ms. Barbara A. Campbell on April 15, 2008. Ms Campbell stated that, if an application looks as though it may require a sequence listing, then the above notice is forwarded to Applicants for an appropriate response. Ms. Campbell also explained that if the application does not require a sequence listing, then Applicant should simply so state.

Accordingly, in response to the Notification to Comply dated March 27, 2008, Applicants respond that the instant application does not disclose a nucleotide sequence and/or an amino acid sequence, and that no "sequence listing" is required. Applicants respectfully request that the application be assigned and forwarded to an Examiner.

It is respectfully submitted that no fee is required as it is believed that the Notification to Comply was sent in error. If, however, the Commissioner determines that any fee is due, please charge it to Deposit Account No. 16-1445.

Respectfully submitted,

Date: JUNE 25, 2008


James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department , MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4903